Nosopharm is a biotech based in Nîmes (South of France) dedicated to anti-infective drug discovery. It aims to address the unmet medical need of the bacterial multi-drug resistance to antibiotics, which is a very concerning issue for hospital-acquired infections.
Despite the strong need for new antimicrobials, very few new, effective antibiotics have been brought to the market in the last few decades. Antibiotic resistance is a major public health threat. Infections caused by resistant bacteria are increasing and causing Europe to face soaring costs both in terms of lives and public health expenditure.
The ENABLE project (European Gram-negative Antibacterial Engine) is working to advance the development of potential antibiotics against Gram-negative bacteria, such as Escherichia coli.
Around 30 European universities, research institutes, and companies (led by GlaxoSmithKline and Uppsala University in Sweden) signed up to the Enable project. They have therefore joined forces in a 6-year program supported by the Innovative Medicines Initiative (IMI) to develop novel antibiotics against Gram-negative pathogens.
The most advanced molecule of Nosopharm’s pipeline (NOSO-95179) is joining the ENABLE project, within IMI’s New Drugs for Bad Bugs (ND4BB) program. This candidate is a 1st-generation Odilorhabdin targeting the Carbapenem-resistant Enterobacteriaceae in hospital-acquired infections
This is a major milestone in the development of our NOSO-95179 candidate. We aim to start IND-enabling studies in 2018 and launch our first-in-man clinical trial in 2019“, – Philippe Villain-Guillot, Co-founder of Nosopharm.
The ND4BB initiative is a series of programs designed to directly address some of the scientific challenges associated with antibacterial drug discovery and development. European Federation of Pharmaceutical Industries and Associations (EFPIA) partners of the initiative include GSK, AstraZeneca, Sanofi, Basilea, and Janssen.
It aims to create join forces between public and private partners in order to bring new antimicrobials closer to patients, to share information and to boost research on improving the uptake of novel drugs and targets in research.
So I know there a lot of acronyms involved across multiple projects, but it is important to highlight that this is a mass network within the EU which is now jointly acting as a force against the rise of antibiotic resistance and hospital-acquired infections.
This is, therefore, a joint collaboration against one of the biggest threats to modern healthcare: indestructible pathogens.